经放化疗联合度伐利尤单抗治疗成功的气管支气管腺样囊性癌：一例报告。
Tracheobronchial Adenoid Cystic Carcinoma Treated Successfully With Chemoradiotherapy Followed by Durvalumab: A Case Report.
机构信息
Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kochi, Japan.
Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kochi, Japan;
出版信息
In Vivo. 2024 May-Jun;38(3):1483-1488. doi: 10.21873/invivo.13595.
BACKGROUND/AIM: Tracheobronchial adenoid cystic carcinoma (ACC) is a rare type of malignancy. Although complete resection is standard treatment for localized ACC, treatment for unresectable ACC has not been established. It is unclear whether concurrent chemoradiotherapy (CCRT) followed by immune checkpoint inhibitor (ICI) therapy is effective for ACC.
CASE REPORT
A 49-year-old man was admitted to our hospital for the treatment of dyspnea and thickening of the bronchial wall from the tracheal carina to the left main bronchus, as observed on a CT scan. Systemic examinations and transbronchial biopsy led to a diagnosis of locally advanced ACC. Although radiotherapy and chemotherapy are not regarded as very sensitive for ACC, a favorable response was obtained with CCRT. Following CCRT, he received ICI therapy with durvalumab for 1 year. The patient has remained in a stable condition 18 months after therapy, with no recurrence.
CONCLUSION
ICI after CCRT might be a promising treatment option for unresectable tracheobronchial ACC.
背景/目的：气管支气管腺样囊性癌（ACC）是一种罕见的恶性肿瘤。虽然局部 ACC 的标准治疗是完全切除，但尚未确定不可切除 ACC 的治疗方法。尚不清楚同步放化疗（CCRT）后联合免疫检查点抑制剂（ICI）治疗是否对 ACC 有效。
病例报告
一名 49 岁男性因呼吸困难和气管隆突至左主支气管的支气管壁增厚就诊于我院，CT 扫描发现这一情况。全身检查和经支气管活检导致诊断为局部晚期 ACC。虽然放疗和化疗对 ACC 的敏感性不高，但 CCRT 获得了良好的疗效。CCRT 后，他接受了 1 年的 durvalumab 免疫检查点抑制剂治疗。治疗后 18 个月，患者病情稳定，无复发。
结论
CCRT 后使用 ICI 可能是治疗不可切除的气管支气管 ACC 的一种有前途的治疗选择。
Zotero 插件